Abstract |
Gene therapy has shown great potential for neurodegenerative diseases with complex pathology. However, its therapeutic effect is limited due to the delivery barriers and its own single function. Herein, self-catalytic small interfering RNA ( siRNA) nanocarriers (S/Ce-PABMS) are developed to catalyze delivery process and treatment process for synergistic treatment of neurodegenerative diseases. On the one hand, the rough surface of the S/Ce-PABMS mediated by ceria (CeO2 ) nanozymes can catalyze cellular uptake in the delivery process, so that S/Ce-PABMS with acetylcholine analogs penetrate the blood-brain barrier and enter neurons more effectively. On the other hand, the CeO2 nanozymes can catalyze the treatment process by scavenging excess reactive oxygen species, and cooperate with siRNA-targeting SNCA to decrease the α- synuclein (α-syn) aggregation and alleviate the Parkinsonian pathology. Moreover, the S/Ce-PABMS treatment reduces the number of activated microglia and regulates the release of inflammatory cytokine, thereby relieving neuroinflammation. After treatment with S/Ce-PABMS, dyskinesia in Parkinson's disease model mice is significantly alleviated. The finding shows that the self-catalytic nanocarriers, S/Ce-PABMS, have great potential in the treatment of neurodegenerative diseases.
|
Authors | Weihong Ji, Yan Li, Huan Peng, Ruichen Zhao, Jie Shen, Yanyue Wu, Jianze Wang, Qiulian Hao, Zhiguo Lu, Jun Yang, Xin Zhang |
Journal | Advanced materials (Deerfield Beach, Fla.)
(Adv Mater)
Vol. 34
Issue 1
Pg. e2105711
(Jan 2022)
ISSN: 1521-4095 [Electronic] Germany |
PMID | 34601753
(Publication Type: Journal Article)
|
Copyright | © 2021 Wiley-VCH GmbH. |
Chemical References |
|
Topics |
- Animals
- Catalysis
- Mice
- Neurodegenerative Diseases
(drug therapy)
- Neurons
(pathology)
- Parkinson Disease
- RNA, Small Interfering
(genetics)
|